glp-1 autoimmune Drugs Lower Risk of Death by 44% in Obesity and Disease Exploring glucagon-like peptide-1 receptor agonists

The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)

Designed to address deficiencies, anemia, neuropathy, and general weakness, its brilliant formulation supports immune function and red blood cell synthesis

Glucagon-Like Peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice

For example, cayenne (capsaicin) and green tea have demonstrated an increase in fat burning in some studies and multi-ingredient thermogenics may also lead to an increased metabolic rate over several hours after consumed